Thomas Sciascia
Founder bei TREVI THERAPEUTICS, INC.
Vermögen: 706 067 $ am 31.03.2024
Aktive Positionen von Thomas Sciascia
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| TREVI THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.03.2011 | - |
| Founder | 01.01.2011 | - |
Karriereverlauf von Thomas Sciascia
Ehemalige bekannte Positionen von Thomas Sciascia
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01.01.2000 | 01.01.2001 |
Quintiles, Inc. (California)
 Quintiles, Inc. (California) Medical/Nursing ServicesHealth Services Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01.01.1997 | 01.01.2000 |
| Boston University | Corporate Officer/Principal | 01.01.1983 | 01.01.1997 |
Penwest Pharmaceuticals Co.
 Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | Chief Tech/Sci/R&D Officer | 01.03.2001 | - |
Ausbildung von Thomas Sciascia
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
| Massachusetts Institute of Technology | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
| Israel | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TREVI THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | Health Technology |
Quintiles, Inc. (California)
Quintiles, Inc. (California) Medical/Nursing ServicesHealth Services Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA. | Health Services |
- Börse
- Insiders
- Thomas Sciascia
- Erfahrung
